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Abstract: The aim of this study was to prepare and evaluate mucoadhesive core-shell 
nanoparticles based on copolymerization of thiolated chitosan coated on poly methyl methacrylate 
cores as a carrier for oral delivery of docetaxel. Docetaxel-loaded nanoparticles with various 
concentrations were prepared via a radical emulsion polymerization method using cerium 
ammonium nitrate as an initiator. The physicochemical properties of the obtained nanoparticles 
were characterized by: dynamic light-scattering analysis for their mean size, size distribution, 
and zeta potential; scanning electron microscopy and transmission electron microscopy for sur-
face morphology; and differential scanning calorimetry analysis for confirmation of molecular 
dispersity of docetaxel in the nanoparticles. Nanoparticles were spherical with mean diameter 
below 200 nm, polydispersity of below 0.15, and positive zeta potential values. The entrapment 
efficiency of the nanoparticles was approximately 90%. In vitro release studies showed a sus-
tained release characteristic for 10 days after a burst release at the beginning. Ex vivo studies 
showed a significant increase in the transportation of docetaxel from intestinal membrane of 
rat when formulated as nanoparticles. Cellular uptake of nanoparticles was investigated using 
fluoresceinamine-loaded nanoparticles. Docetaxel nanoparticles showed a high cytotoxicity 
effect in the Caco-2 and MCF-7 cell lines after 72 hours. It can be concluded that by combining 
the advantages of both thiolated polymers and colloidal particles, these nanoparticles can be 
proposed as a drug carrier system for mucosal delivery of hydrophobic drugs.
Keywords: poly methyl methacrylate, mucoadhesive, cytotoxicity
Introduction
Oral drug delivery is the most acceptable method of drug delivery to the body. It is 
particularly important for cytotoxic medicines. These drugs are generally available 
as injectable dosage forms and their administration requires experienced personnel, 
patient’s presence at the hospital, and specific care, and thus poses many problems for 
the patients. Some of the advantages of oral chemotherapy include: increasing the drug 
efficacy and half-life, preventing excess increase in the blood concentration and the 
increase of drug toxicity, as well as decreasing the drug side effects in the body.1,2 For 
these reasons, many studies have been carried out in recent years on the administra-
tion of cytotoxic drugs in oral dosage form.2–6 Docetaxel (DTX) is a semisynthetic 
taxoid extract from Taxus baccata (European yew tree) and is one of the most effec-
tive drugs in chemotherapy.7 The mechanism of this drug on cancer cells is through 
inhibiting microtubule depolymerization, and studies show that the cytotoxic effect 
of DTX on tumor cells is about two times that of paclitaxel.8 DTX is used as an effec-
tive drug against breast, ovarian, lung, head, and neck cancers9–11 and is available only International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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in the parenteral dosage form (Taxotere;® sanofi-aventis). 
Because of poor solubility of DTX in water, it is formulated 
as a solution with a high amount of Tween 80/ethanol. High 
concentration of solubilizers in its formula causes toxic 
effects and allergic   reactions.12 Like most effective drugs used 
in chemotherapy, it is not absorbable orally and has a very 
low bioavailability. In addition to its poor aqueous solubil-
ity, it is eliminated through the first pass extraction by the 
cytochrome P-450 processes and the action of efflux pump 
of p-glycoproteins (p-gp) in the liver and intestine.13,14 The 
use of surface-modified polymeric nanoparticle (NP) systems 
may be regarded as an effective means of overcoming these 
problems. NPs, due to their unique properties such as their 
small size and certain surface characteristics, can protect 
drugs from p-gp and cytochrome P450, protect drugs from the 
destructive factors in the gastrointestinal tract, and increase 
their permeability through the gastrointestinal barrier.2 
Considering the nature of these NPs, an interesting aspect 
in preparing surface-modified NPs is based on the synthesis 
of amphiphilic copolymers.5,15–18 Synthesizing copolymers 
using polyalkylcyanoacrylate and a polysaccharide such as 
chitosan or dextran, as described by Chauvierre et al,18 is a 
very favorable approach due to the simultaneous formation of 
NP and copolymer in a single stage. Here, NP formation is by a 
radical emulsion polymerization method, which is initiated by 
the creation of a free radical at the end of the polysaccharide 
chain, through an initiator like cerium ion in acidic medium; 
these free radicals cause the polymerization of cyanoacrylate 
monomers and the formation of a linear block copolymer. 
Since this reaction is carried out in an aqueous medium, the 
hydrophobic polymer tends to go inside the NPs at the same 
time that the particle is formed, and creates a hydrophobic core 
coated with a hydrophilic polysaccharide. This method results 
in the formation of a very stable NP suspension.17–19
One of the polymers which has attracted much interest 
is chitosan, due to its excellent characteristics for preparing 
surface-modified NPs. Chitosan is a nontoxic, biocompatible, 
and biodegradable polymer that is able to bind to mucus due 
to ionic interactions between its primary amino substructures 
and the sialic acid and sulfonic acid substructures of the 
mucus.20
The mucoadhesive properties of chitosan are increased 
intensively by the immobilization of thiol groups on its 
structure.21 The mucoadhesive properties of chitosan have 
been shown to improve 140-fold due to the immobilization 
of thiol groups on the polymer.21 The reason for this is the 
formation of disulfide bonds between the thiolated polymer 
and cysteine-rich subdomains of the mucus gel layer.22 
The thiolated derivatives cause an increase in permeability 
through the intestine membrane by the mechanism of the 
regeneration of glutathione and inactivation of the protease 
enzymes in the gastrointestinal tract via absorbing and 
removing the bivalent cations from the medium.6,23 All 
these properties make the thiolated chitosan a very desirable 
material for increasing the absorption of peptides and NPs 
through the mucosa.24 Due to these favorable characteristics 
of chitosan, many researchers in recent years have investi-
gated the preparation and evaluation of NPs obtained from 
the copolymerization of acrylate derivatives, coated with 
chitosan or its derivatives.17–19,25
In this study, the potential use of NPs prepared by the 
copolymerization of poly methyl methacrylate (pMMA) and 
chitosan–glutathione conjugates as a carrier for oral delivery 
of a hydrophobic drug (DTX) was investigated.
Materials and methods
Materials
DTX was obtained from Cipla (Mumbai, India). Chitosan 
(ChitoClear) with a medium molecular weight and degree 
of deacetylation of about 89% was purchased from 
Primex (Karmoy, Norway). L-Glutathione-reduced form 
(GSH), 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) hydrochloride, N-hydroxysuccinimide (NHS), 
methyl methacrylate (MMA), ammonium cerium nitrate, 
sodium nitrite, hydrochloric acid, glacial acetic acid, 
sodium hydroxide, and potassium hydrogen phosphate 
were all purchased from Merck (Darmstadt, Germany). 
Fluoresceinamine (FA)   isomer I and Ellman’s reagent, 
5,50-dithiobis (2-nitro benzoic acid), were obtained from 
Sigma-Aldrich (St. Louis, MO). 3-(4,5- dimethylthiazol-2-
yl)-2,5-diphenyl tetrazolium   bromide) (MTT) was purchased 
from Sigma-Aldrich. Caco-2 and MCF-7 cell lines were 
obtained from the Pasteur Institute (Tehran, Iran). All other 
chemicals were of analytical grade.
Depolymerization of chitosan
Chitosan was selectively depolymerized following the 
method developed by Huang et al.26 Briefly, 100 mL of a 2% 
(w/v) chitosan (400,000 g/mol) solution in 6% (v/v) acetic 
acid solution was prepared. Then the dissolved chitosan 
was depolymerized at room temperature under stirring with 
10 mL of NaNO2 solutions in water at different concen-
trations (7.0, 2.7, and 1.6 g/L), to obtain the desired final 
molecular weight of 20,000, 50,000, and 100,000 g/mol, 
respectively. After 1 hour of reaction, precipitated chitosan 
was obtained by raising the pH to 9.0 by addition of 4N International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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NaOH. The white-yellowish solid was filtrated, washed thor-
oughly with acetone, and re-dissolved in a minimum volume 
of acetic acid 0.1 N (40 mL).
Purification was carried out by subsequent dialyses 
against purified water (Sigma dialysis tubes, molecular 
weight cutoff, 12 kDa). The dialyzed product was lyophilized 
using a LyoTrap plus Freeze dryer (LTE Scientific, Oldham, 
UK), and the yellowish lyophilized product was then stored 
at 4°C until use. Products obtained were called Chito.20, 
Chito.50, and Chito100 depending on their theoretical 
molecular weight.
The average molecular weights of the prepared chitosans 
were determined by a viscometric method as described in 
our previous work.5
chitosan thiolation
Thiolated chitosan was prepared with covalent attachment of 
reduced glutathione to different molecular weight of chito-
san according to the slightly modified method described by 
Atyabi et al and Kafedjiiski et al as follows:5,27
One gram of chitosan was dispersed in 50 mL demineral-
ized water by stirring, then 10 mL HCl (1 mol/L) was added 
and finally dissolved by the addition of demineralized water 
to obtain a 1% (w/v) polymer solution. The pH was adjusted 
to 6.0 by the addition of NaOH (5 mol/L). Afterwards, 
5 g of reduced glutathione in 10 mL demineralized water 
was added to the above solution under continuous stirring. 
EDC and NHS were then added in a final concentration of 
200 mmol/L each. The pH was readjusted to 6.0 by adding 
NaOH (5 mol/L). The reaction mixture was incubated for 
15 hours at room temperature under constant stirring. To 
eliminate unbound reagents, the resulting polymer conjugate 
was dialyzed using dialysis tubing (molecular weight cutoff 
12 kDa), first against 5 mmol/L HCl, twice against 5 mmol/L 
HCl containing 1% NaCl, and finally twice against 1 mmol/L 
HCl. Controls were prepared in the same way but omitting 
EDC and NHS during the coupling reaction. Finally, the 
frozen aqueous polymer solutions were lyophilized at −50°C 
and 0.01 mbar (LyoTrap plus; LTE Scientific, UK) and stored 
at 4°C until further use.
The amount of thiol groups immobilized on chitosan–
GSH conjugate was determined using Ellman’s reagent and 
the spectrophotometric method.27–29
Preparation of thiolated  
chitosan-pMMA NPs
The NPs were prepared by using a modified radical 
polymerization method. Conjugated chitosan (37.5 mg) with 
different theoretical molecular weight (20, 50, and 100 kDa) 
was dissolved in 4 mL nitric acid (0.2 mol/L) in a two-necked 
flask at 40°C, under gentle stirring and nitrogen bubbling. 
After 10 minutes, under vigorous magnetic stirring, a solu-
tion of 0.08 mol/L cerium IV ammonium nitrate (CAN) in 
0.2 mol/L nitric acid and MMA was added to obtain a 5-mL 
solution. Nitrogen bubbling was continued for an additional 
10 minutes. The reaction was allowed to continue at 40°C 
under gentle stirring for 40 minutes. After cooling to room 
temperature, the pH of the obtained suspension was adjusted 
to 4.5 by addition of sodium hydroxide (1 N) drop-wise. The 
NP suspension was then purified by dialysis (Sigma dialysis 
tubes, molecular weight cutoff, 12 kDa) against 1 L of acetic 
acid solution (16 µmol/L) in demineralized water, twice for 
90 minutes and once overnight. The frozen NP suspensions 
were lyophilized at −50°C and 0.01 mbar and stored at 4°C 
until further use.
Determination of the thiol group  
content of thiolated chitosan-coated  
pMMA (cht-gSh-pMMA) NPs
To quantify thiol group content of the NPs, iodine titration was 
performed as described by Bravo-Osuna et al and Kast and 
Bernkop-Schnürch.24,30 Twenty milligrams of the lyophilized 
NPs was hydrated in 6 mL of demineralized water. Follow-
ing adjustment of pH to 2–3 with 1 mol/L HCl, the solution 
became clear. Then 500 µL of aqueous starch solution (1%) 
was added. The samples were titrated with an aqueous iodine 
solution (1 mmol/L) until a permanent light blue color was 
maintained.
Preparation of DTX- or FA-loaded NPs
The anticancer drug-loaded NPs were prepared using 
  Chito.20. After adding acidic solution of CAN, DTX was 
dissolved in 0.5 mL of methanol under stirring, and 0.25 mL 
MMA was added to obtain a clear solution. Under vigor-
ous magnetic stirring, a solution of DTX was added in a 
two-necked flask. Nitrogen bubbling was continued for an 
additional 10 minutes. The added amount of DTX was in the 
range from 1% to 4% (w/w) based on the weight of MMA 
and thiolated chitosan. The reaction was allowed to continue 
at 40°C under gentle stirring for 40 minutes. After adjusting 
the pH of the obtained suspension to 4.5, the NP suspension 
was purified by dialysis. The amount of DTX in the obtained 
NPs was measured by high-performance liquid chromatogra-
phy (HPLC). Isocratic reversed-phase HPLC was performed 
using a Knauer HPLC system (Knauer, Berlin, Germany) 
with a 5 µ Bondapak C18 column (Waters, Milford, MA). International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The mobile phase consisted of 75:25 (v/v) methanol/water 
and was delivered at a flow rate of 1.0 mL/min. Eluted 
  compounds were detected at 227 nm using a Spectra100 
UV-Vis detector. The FA-loaded NPs were prepared in the 
same way except for the addition of 0.25% (w/v) FA to the 
monomer (MMA) solution instead of DTX.
Size distribution of NPs
The mean diameter and size distribution of the NPs were 
determined by dynamic light scattering using Zetasizer® 
(Nano-ZS, Malvern, Instruments, Malvern, UK). All 
dynamic light scattering measurements were carried out at 
a wavelength of 633 nm at 25°C with an angle detection of 
90°. The samples were diluted in acetic acid (16 µmol/L) 
in deionized water, three subsequent measurements were 
determined for each sample, and the result was expressed 
as mean size ± standard deviation.
Determination of zeta potential
The zeta potential measurements were performed by Laser 
Doppler Electrophoresis using Zetasizer (Nano-ZS). To 
maintain a constant ionic strength, the samples were diluted 
(1:50 v/v) in NaCl 1 mmol/L (pH 6.5).3 Each sample was 
measured three times.
Differential scanning  
calorimetry (DSc)
DSC was performed to investigate the physical status of DTX 
in the NPs. DSC scans of DTX, empty and DTX-loaded 
NPs were performed on a Mettler DSC 823e equipped with 
Mettler STARe system software for the data acquisition. The 
samples were scanned at a speed of 5°C/min in a 30°C–250°C 
temperature range.
Scanning electron microscopy
The surface morphology of the NPs was evaluated by using 
a scanning electron microscope (SEM XL 30; Philips, 
  Eindhoven, The Netherlands). NP suspensions were suc-
cessively diluted in deionized water to 1/50 (v/v). The dilu-
tions were spread on an aluminum disc and dried at room 
temperature before the analysis. The dried NPs were then 
coated with a thin layer of gold metal using a sputter coater 
(SCD 005; Bal-Tec, Pfaffikon, Switzerland).
Transmission electron microscopy (TeM)
Transmission electron microscopy (TEM; CEM 902A; Zeiss, 
Oberkochen, Germany) was used to examine the struc-
ture and the topography of the NPs. NP suspensions were 
diluted in demineralized water to 1/100 (v/v), and prior to 
observation, the NPs were negatively stained with a solution 
of 1% phosphotungstic acid.
Drug loading and entrapment efficiency
The entrapment efficiency (EE) of the process was determined 
indirectly upon separation of the NPs by ultracentrifugation 
at 25,000 rpm, 8°C for 30 minutes from the aqueous medium 
containing free DTX. The amount of free DTX in the super-
natant was measured using HPLC. The EE of DTX NPs 
was calculated as the ratio of DTX loaded into the NPs with 
respect to the total amount of DTX used for preparation of 
the original mixture as follows:
EE (%) = (DTXt – DTXf)/DTXt × 100,
where DTXt is the total amount of DTX used for preparation 
of the original mixture and DTXf is the free DTX amount 
recovered in the supernatant. All samples were measured in 
triplicate.
Drug loading (DL) was calculated as follows:
DL (%) = (Weight of loaded drug/Weight of NPs) × 100.
In vitro drug release study
Drug release from DTX-loaded NPs was studied by 
  incubating the NPs in phosphate-buffered solution (PBS), 
at pH 7.4, at 37°C. Two milligrams of NPs was dispersed in 
5 mL of release medium (PBS of pH 7.4 containing 0.1% w/v 
Tween 80) in a dialysis tube (Sigma dialysis tubes, molecular 
weight cutoff, 12 kDa), and the closed dialysis bag immersed 
in 20 mL release medium in a centrifuge tube. Tween 80 was 
used to increase the solubility of DTX in the buffer solution 
to maintain sink condition. The tube was placed in a shaker 
bath at 37°C and shaken horizontally at 100 cycles/min. At 
given time intervals, 15-mL samples were withdrawn and 
replaced with the same volume of fresh medium. The samples 
were filtered through a 0.22-µm filter and were analyzed for 
the amount of DTX using HPLC.
In vitro cytotoxicity of DTX-loaded NPs
Human colon adenocarcinoma cells (Caco2) and MCF-7 cells 
were used for the evaluation of cell viability of DTX-
loaded NPs. Separately, Caco-2 and MCF-7 cells were 
incubated in 96-well transparent plates (Costar, Chicago, 
IL) at 1 × 104 cells/well (100 µL). After 12 hours the old 
medium was removed, and the cells were incubated in the 
medium containing DTX or DTX-loaded NPs. Because of 
the cytotoxic effects of Tween 80,4,31 DTX was dissolved in International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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dimethyl sulfoxide (DMSO) instead of Tween 80/ethanol/
saline as   solvent. DTX was dissolved in DMSO at a proper 
concentration and diluted 100-fold with growth medium. 
DTX-loaded NPs were then dispersed into the purified water, 
and after dilution with growth medium were added to each 
well at equivalent drug concentrations ranging from 0.1 
to 1000 ng/mL. After 72 hours incubation, 20 µL of MTT 
(3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazonium-
bromide) solution (5 mg/mL) was added to each well of the 
plate. After 4 hours, 100 µL DMSO was added to each well, 
and the absorbance of the solution was measured at 570 nm 
and reference wavelength at 690 nm by a microplate reader 
(Anthos 2020; Anthos Labtec Instruments, Wals, Austria).
Caco-2 cell uptake of fluorescent NPs
For qualitative uptake studies, the Caco-2 cells were seeded 
in the chambered glass system (Lab-Tek; Nunc International 
Co., Naperville, IL). Cells were washed four times after incu-
bation with FA-loaded NPs for 2 hours and then fixed by a 
cold mixture of methanol/acetone (50:50 v/v) for15 minutes 
at room temperature. The cells were washed twice with PBS 
and mounted in mounting medium consisting of Na2HPO4 
and acetic acid (pH 5.5)/glycerol (50:50 v/v) to be observed 
by fluorescence microscope (λext: 540 nm and λem: 580 nm; 
BX40; Olympus, Tokyo, Japan). The fluorescent images 
were taken by DP70 digital imaging system (Olympus) and 
analyzed by Olysia imaging software (Olympus).
ex vivo study
The everted sac method was chosen for measurement of 
transportation of DTX across the intestine barrier. It was 
carried out according to the slightly modified method that 
was described by Barr and Riegelman,32 as follows.
First, a section of about 5 cm of the jejunum was removed 
from a male rat under ketamine (50 mg/kg) and chlorprom-
azine (10 mg/kg) anesthesia and washed with Krebs–Ringer 
bicarbonate solution of pH = 7.4. This section was then gently 
inverted with a glass rod, and a tube was inserted in one side 
of the section and tied securely with tape. The other side of 
the intestine was tied, and 1 mL Krebs–Ringer bicarbonate 
solution was poured through the hypodermic needle in the 
tube. The gut sac was placed in a medium saturated with 95% 
O2, 5% CO2, and contained the test sample in Krebs–Ringer 
bicarbonate solution at 37°C. The test samples used include: 
(1) DTX (1 mg) as Taxotere®, and (2) Chito.20-GSH-DTX 
4% NPs (equivalent to 1 mg of DTX). In absorption studies, 
an O2 and CO2 mixture was bubbled into the intestinal mucosa 
to obtain intestinal peristaltic movement. At certain periods 
of time, 0.5-mL samples were drawn from inside the intestine 
and replaced with the same volume of fresh medium. The 
amount of transported DTX in the samples was measured 
by the HPLC method.
Results and discussion
chitosan depolymerization  
and characterization
Several studies have demonstrated that the molecular weight 
of chitosan is very important to NP properties such as par-
ticle size,33 paracellular permeability,34 and immunological 
response.35 Due to high molecular weight and thus high 
viscosity and poor solubility at physiological pH range of 
the commercial chitosan, the use of low-molecular-weight 
chitosan is preferred in particular drug delivery systems.36
Depolymerization of chitosan was carried out via an 
oxidative process by NaNO2 as a simple and reproducible 
method. Molecular weights of depolymerized chitosan 
determined by capillary viscometry measurement are shown 
in Table 1. It has been demonstrated that various molecular 
weights of chitosans could be obtained by changing the 
chitosan/NaNO2 molar ratio.37,38 As expected, using distinct 
amounts of NaNO2 produced chitosans with molecular 
weights in accordance with theoretical values.5,33
Thiolated chitosan preparation  
and quantification
Table 1 summarizes the amounts of free thiol groups, 
disulfide bonds, and total sulfhydryl groups immobilized on 
chitosan-GSH conjugates. The free thiol content and total 
Table 1 Molecular weights of depolymerized chitosan and thiolated chitosan characterization (n = 3)
Chitosan 
type
NaNO2 
mg/mL
Determined 
Mw (g/mol)
Free thiol 
(μmol/g)
Disulfide content  
(μmol/g)
Total amount of 
sulfhydryl groups (μmol/g)
chito.20 7.0 19,230 93.70 ± 4.20 552.66 ± 12.14 646.36 ± 8.05
chito.50 2.7 53,850 86.68 ± 5.70 532.17 ± 10.53 618.85 ± 5.61
chito.100 1.6 97,520 69.11 ± 4.72 529.04 ± 18.57 598.15 ± 23.31
Parent – 478,704 – – –
Abbreviation: Mw, molecular weight.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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sulfhydryl groups of different molecular weights of chitosan 
is very similar to the results obtained by Bravo-Osuna et al.39 
The results indicated that when the molecular weight of 
chitosan increased, the difficulty of the thiol-bearing agent to 
reach the amino groups of chitosan was increased, and fewer 
sulfhydryl groups could be fixed on the polymer.
NP preparation and characterization
The mean hydrodynamic diameter, polydispersity index 
(PDI), zeta potential, and thiol content of NPs prepared 
using different molecular weights of chitosan-GSH in a fixed 
amount of MMA and CAN are presented in Table 2.
The mean size of particles obtained by different molecular 
weights of thiolated chitosan, with values varying from 153 
to 264 nm, demonstrated an incremental increase in accor-
dance with the molecular weight of chitosan. This result is 
very similar to the results obtained by Bravo-Osuna et al.39 
The zeta potential of particles was positive, indicating that 
the negative surface charge of noncoated pMMA40 was 
completely covered by the cationic chitosan. According to 
the significant effect of particle size and type of surface coat-
ing on the cellular uptake of polymeric NPs41 in this study, 
chitosan with low molecular weight (20,000) was used for 
preparation of DTX NPs. Smallest NPs with most free thiol 
on their surface were produced using Chito.20.
DTX-loaded NPs characterization
The size, PDI, and zeta potential of DTX-loaded NPs pre-
pared by Chito.20-GSH and different amounts of DTX in a 
fixed amount of MMA and CAN are seen in Table 3. The 
particle size is a very important parameter for cellular uptake 
of the NPs. The permeability of the NPs through the intestinal 
mucosa decreases when the particle size reaches 500 nm.41–43 
The mean diameter of the NPs in this study was 168–186 nm, 
which is suitable for intestinal uptake of NPs.
As can be seen in Table 3, the zeta potential of the NPs 
was positive due to their chitosan coating with free amino 
groups.33 This is favorable for making electrostatic bonds 
with negatively charged mucosa and preventing elimination 
through the alimentary canal. There is an inverse relation-
ship between the concentration of entrapped DTX and zeta 
potential value of particles. The SEM image of the NPs shows 
that they are spherical (Figure 1). The figure also confirms the 
size of the NPs measured by Zetasizer shown in Table 3.
Figure 2 shows the TEM image of DTX-loaded NPs. The 
core and coat of NPs can be recognized in this figure.
As given in Table 3, all NPs have a desired PDI less than 
0.2 indicating a homogenous size distribution. Commonly, 
the PDI is an index of stability of all the nanosuspensions.
Entrapment efficiency and drug loading  
of NPs
The EE and DL of the NPs is shown in Table 3. The EE of the 
NPs was determined with an indirect method after isolation 
of NPs by centrifuging them as described above. Ideally, a 
successful nanoparticulate system should have a high DL 
capacity. As seen in Table 3, the EE of Chito.20-GSH-DTX 
1%, 2%, 3%, and 4% NPs are 92.4, 91.1, 88.9, and 93.6%, 
respectively. The maximum EE was related to NPs with 4% 
DTX. This high EE might be due to the tendency of DTX 
as a hydrophobic molecule to enter the hydrophobic core 
(pMMA) of the NPs.
Table 2 Mean hydrodynamic diameter, polydispersity index, zeta potential, and free thiol of nanoparticles made by different molecular 
weight of chitosan-gSh
Formulation Mean hydrodynamic 
diameter (nm)
Polydispersity 
index
Zeta 
potential
Free thiol 
(μmol/g)
chito.100-gSh-pMMA 264 ± 18.1 0.192 33.5 47.25 ± 6.04
chito.50-gSh-pMMA 201 ± 10.2 0.090 39.2 63.32 ± 4.86
chito.20-gSh-pMMA 153 ± 9.0 0.124 41.5 72.37 ± 6.32
Abbreviations: gSh, glutathione; pMMA, poly methyl methacrylate.
Table 3 characterization of nanoparticles made by chito.20 and varying concentrations of DTX
Formulation DTX (mg) Size PDI Zeta 
potential
Loading 
efficiency
EE
chito.20-gSh-DTX 1% 2.72 168 ± 4.0 0.07 36.9 ± 0.4 8.5% 92.44%
chito.20-gSh-DTX 2% 5.45 174 ± 5.5 0.10 36.2 ± 0.8 10.34% 91.08%
chito.20-gSh-DTX 3% 8.17 184 ± 6.0 0.04 35 ± 0.3 14.5% 88.89%
chito.20-gSh-DTX 4% 10.90 186 ± 10.6 0.12 30.1 ± 2.2 20.39% 93.56%
Abbreviations: DTX, docetaxel; EE, entrapment efficiency; GSH, glutathione; PDI, polydispersity index.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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The DL of Chito.20-DTX NPs was between 8.5% and 
20.4%. A high DL capacity was expected, due to the hydro-
phobicity of DTX.
Physical status of DTX in the NPs
DSC studies were performed to investigate the physical status 
of DTX in the NPs. Figure 3 shows the DSC thermograms of 
free DTX, unloaded, and drug-loaded NPs. Free DTX showed a 
sharp endothermic melting peak at about 169°C related to DTX. 
However, no melting peak could be detected for the NP formu-
lations. This shows that DTX in the NPs is in an amorphous or 
disordered crystalline phase, miscible in polymeric NPs.
In vitro drug release study
The in vitro release profile of the DTX-loaded NPs is shown 
in Figure 4. It shows a sustained Fickian release profile, sug-
gesting that the hydrophobic core acts as a barrier against 
the release of entrapped DTX from the polymeric matrix into 
the aqueous solution.
Fluorescent microscopy image
Figure 5 shows the fluorescent microscopy image of 
Caco-2 cells after 2 hours incubation with FA-loaded NPs. 
As can be seen in this figure, after 2 hours incubation, the 
FA-loaded NPs have been internalized by the Caco-2 cells, 
which are located in the cytoplasm around the nucleus.
In vitro cell viability of NPs
Figure 6 shows the viability of Caco-2 and MCF-7 cells after 
72 hours incubation time with DTX-loaded NPs in com-
parison with free DTX drug at the same concentration (0.1, 
1.0, 10, 100, and 1000 ng/mL). In our previous study, it was 
shown that the blank NPs did not show any cytotoxic effect 
on the Caco-2 and MCF-7 cells.44 The results in this study 
indicated that the drug entrapped in thiolated Chito.20 NPs 
had more cytotoxic effect than the free drug for Caco-2 cells 
at most concentrations (P , 0.05) and had equal cytotoxic-
ity for MCF-7 after 72 hours. Based on the result of in vitro 
release studies (Figure 4), after 72 hours, approximately 70% 
of the drug is released from the NPs. Thus, more cytotoxicity 
effect of the NPs is not only related to the DTX released from 
Figure 1 Scanning electron micrograph of docetaxel-loaded nanoparticles.
Figure 2 Transmission electron micrograph of a docetaxel-loaded nanoparticle.
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Figure 3 Differential scanning calorimetry thermograms of the docetaxel (DTX)-
loaded chito.20 nanoparticles (A), blank chito.20 nanoparticles (B), and pure   
DTX (c). 
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Figure 4 In vitro docetaxel (DTX) release profiles from DTX-loaded nanoparticles 
in phosphate-buffered solution (ph = 7.4, 37°c). Data are represented as mean ± 
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the NPs but probably also because of cell uptake of the NPs 
and/or better penetration of NPs into the cells. The site of 
action of DTX is the cytoplasm, and NPs act as intracellular 
depots that slowly release the loaded therapeutic agent into 
the cellular cytoplasm. This increase of cytotoxic effects of 
NPs after a period of time is in agreement with previous 
reports.45,46
ex vivo study
In this study, we used the everted intestinal sac method for 
measuring the transporting of DTX from the intestinal barrier. 
Figure 7 shows the amount of DTX transported across the 
intestinal barrier. As seen in the figure, after 120 minutes, 
the amount of DTX transported from the intestinal barrier 
with Chito.20-GSH NPs was significantly higher than free 
DTX. Consequently, on the basis of these results, it was 
hypothesized that transportation of DTX across the intestine 
membrane is low, and the mucoadhesive NPs can increase 
DTX transport by opening tight junctions and bypassing the 
efflux pump of p-gp.
Conclusion
In this work we applied mucoadhesive thiolated chitosan 
pMMA NPs as a carrier for oral delivery of DTX. DTX was 
loaded into the pMMA thiolated chitosan NPs using a modi-
fied radical polymerization method. This method has some 
advantages for obtaining a drug carrier, such as elimination 
of organic solvent and surfactants and preparation of NPs 
under mild conditions. The size of the NPs was small and 
size distribution was narrow. EE was high (around 90%), 
and in vitro release studies showed the potential of NPs 
for extended release of DTX in medium solution. It seems 
Figure 5 Fluorescence microscopic images of caco-2 cells after 2 hours incubation 
with fluoresceinamine (FA)-loaded nanoparticles at 37°c. As shown in the image, the 
yellow fluorescence of the FA-loaded nanoparticles is distributed in the cytoplasm, 
indicating the uptake of nanoparticles by the cells.
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Figure 6 Viability of caco-2 cells (A) and McF-7 (B) after 72 hours cell culture 
with DTX-loaded chito.20-gSh nanoparticles (♦) in comparison with DTX () 
at different concentrations (n = 6). Percentage survival was assessed by MTT assay. 
Data are mean ± standard deviation (n = 6).
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Figure 7 Profile of the amount of DTX transported in medium (pH 7.4) as a 
function of time: chito.20 gSh nanoparticles (♦), DTX (). experiments were 
carried out in triplicate (n = 3).
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that the penetration ability of DTX-loaded NPs prepared 
with thiolated chitosan into the cancer cells causes more 
cytotoxic effect of NPs versus free drug after 72 hours. 
Such hydrophobic and mucoadhesive NPs seem to be very 
promising vehicles for oral delivery of hydrophobic drugs 
such as taxanes.
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